Printer Friendly

-FDA greenlights Cellavision's body fluid analysing application.

NORDIC BUSINESS REPORT-September 27, 2011--FDA greenlights Cellavision's body fluid analysing application(C)2011 M2 COMMUNICATIONS

27 September 2011 - Swedish Cellavision AB (STO:CEVI) said today the US Food and Drug Administration (FDA) had approved its application for body fluid analysis for use on the cell morphology system Cellavision DM1200.

The application can be used to analyse various body fluids, including spinal, synovial and pleural fluid.

Following the clearance, Cellavision will be able to offer medium-size laboratories in the USA a fully automated analyser for both blood and other body fluids, Ron Hagner, vice president at Cellavision North America, said.

The Swedish company has two cell morphology systems -- Cellavision DM96 for use in big laboratories and Cellavision DM1200 for use in medium-size laboratories. The Cellavision body fluid application has been available on DM96 since 2008 and on DM1200 outside the USA since 2010.

In the USA, Cellavision sells its products via a local subsidiary and via two distribution partners.

((Comments on this story may be sent to>PDSeptember 27, 2011>JNNORDIC BUSINESS REPORT.PRICEDATENOT APPLICABLE.DAY

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:US Food and Drug Administration
Publication:Nordic Business Report
Article Type:Brief article
Geographic Code:4EUSW
Date:Sep 27, 2011
Previous Article:-Maersk near wrapping up LNG unit divestment deal - paper.
Next Article:-Skanska announces investment in US lab building.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters